Pages that link to "Q34431300"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. (Q34431300):
Displaying 50 items.
- Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices (Q26748229) (← links)
- Optimizing therapy early in multiple sclerosis: An evidence-based view (Q26783070) (← links)
- An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations (Q27009769) (← links)
- Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations (Q30993770) (← links)
- Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial (Q33736198) (← links)
- Natalizumab in Multiple Sclerosis: Long-Term Management (Q33754882) (← links)
- Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes (Q33814485) (← links)
- Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis (Q33825885) (← links)
- Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) (Q33891255) (← links)
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. (Q34803324) (← links)
- Comparative efficacy of switching to natalizumab in active multiple sclerosis (Q35469575) (← links)
- Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. (Q35684256) (← links)
- Natalizumab in the pediatric MS population: results of the Italian registry (Q35788938) (← links)
- Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients (Q35884067) (← links)
- Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP) (Q35895287) (← links)
- Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab (Q36073992) (← links)
- Halo and spillover effect illustrations for selected beneficial medical devices and drugs (Q36133467) (← links)
- Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis (Q36484448) (← links)
- Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. (Q36789883) (← links)
- Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. (Q38364547) (← links)
- Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy (Q38371740) (← links)
- Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update (Q38616689) (← links)
- Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children (Q38619288) (← links)
- Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. (Q38636586) (← links)
- Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study (Q38758444) (← links)
- Autologous hematopoietic cell transplantation in multiple sclerosis. (Q38818703) (← links)
- Treatment decisions in multiple sclerosis - insights from real-world observational studies. (Q39022643) (← links)
- Natalizumab treatment of multiple sclerosis: new insights (Q39048568) (← links)
- Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy (Q39269762) (← links)
- Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies (Q39732691) (← links)
- The role of natalizumab in the treatment of multiple sclerosis: benefits and risks (Q40061894) (← links)
- Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings (Q40498719) (← links)
- MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance (Q40619670) (← links)
- Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients (Q41126166) (← links)
- Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. (Q41386664) (← links)
- Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis (Q41626879) (← links)
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies (Q41926094) (← links)
- Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. (Q42665193) (← links)
- The importance of collecting structured clinical information on multiple sclerosis (Q42747344) (← links)
- Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan (Q47148150) (← links)
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis (Q47198260) (← links)
- Pharmacological and non-pharmacological therapies of cognitive impairment in multiple sclerosis (Q47978062) (← links)
- Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation (Q48260043) (← links)
- Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis (Q48271331) (← links)
- Benefit-Risk Analysis for Decision-Making: An Approach (Q48770147) (← links)
- Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years (Q48821433) (← links)
- Long-term registries: Answering tough questions with big data? (Q49353031) (← links)
- JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus. (Q54230581) (← links)
- Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management (Q59354824) (← links)
- Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings (Q64038865) (← links)